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Nintedanib is a new triple angiokinase inhibitor that potently blocks the proangiogenic 
pathways mediated by vascular endothelial growth factor receptors, platelet-derived 
growth factor receptors, and fibroblast growth factor receptors. Evidence about its 
efficacy in addition to second-line chemotherapy in non-small cell lung cancer (NSCLC) 
has been produced by two large randomized phase III clinical trials (LUME-Lung 1 and 
LUME-Lung 2), conducted in patients with pretreated NSCLC, without major risk factors 
for bleeding. In the LUME-Lung 1, the addition of nintedanib to docetaxel significantly 
improved progression-free survival, which was the primary end point of the trial (3.4 vs. 
2.7 months, hazard ratio: 0.79; p =  0.0019). Furthermore, a significant improvement 
in median overall survival (from 10.3 to 12.6  months) was observed in patients with 
adenocarcinoma histology, with a greater advantage in patients who progressed within 
9 months after start of first-line treatment (from 7.9 to 10.9 months) and in patients who 
were most refractory to first-line chemotherapy (from 6.3 to 9.8 months). Adverse events 
were more common in the docetaxel plus nintedanib group, and they included diarrhea 
and increased liver enzymes, while no statistically significant increase in the incidence of 
bleeding and hypertension events by the addition of nintedanib was observed. On these 
bases, the combination of docetaxel and nintedanib can be considered a new option 
for the second-line treatment for patients with advanced NSCLC with adenocarcinoma 
histology. Future challenges are the identification of predictive factors to help the decision 
of using nintedanib in eligible patients.
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iNTRODUCTiON
In recent years, a better understanding of the biology of cancer led to the development of molecular 
targeted therapies that have radically changed the treatment of many solid tumors, including non-
small cell lung cancer (NSCLC). The new tailored agents, such as epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase inhibitors, are able to 
inactivate specific molecular alterations that occur in specific oncogenes, which cause cancer cell 
survival strictly dependent on such aberrant genes, as explained by the “oncogene addiction theory” 
(1). However, only a minority of tumors are oncogene addicted, and chemotherapy remains the only 
treatment available for the majority of cancer patients.
FiGURe 1 | Chemical structure of Nintedanib.
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In this setting, targeting the angiogenesis pathways represents 
an alternative and attractive strategy, inasmuch as tumor devel-
opment, progression, and metastasis are demonstrated strongly 
linked to angiogenesis. Angiogenesis is a very complex process, 
which is highly regulated by many molecules with both proangio-
genic and antiangiogenic activity. The tumor microenvironment 
is composed of hyperproliferating cells that need large amounts of 
oxygen and nutrients. Such cells are able to deregulate the angio-
genic process inducing an abnormal secretion of proangiogenic 
factors and the consequent development of disorganized, tortu-
ous, enlarged, high permeable blood vessels, which are needed 
for both tumor growth and its metastatic potential (2). Therefore, 
angiogenic pathways have been investigated as potential thera-
peutic targets in patients with NSCLC (3). Several antiangiogenic 
agents have been developed, including monoclonal antibody 
anti-vascular endothelial growth factor (VEGF) such as bevaci-
zumab or vascular endothelial growth factor receptor (VEGFR) 
TKIs, such as sorafenib and sunitinib. In particular, bevacizumab 
in combination with platinum-based chemotherapy has dem-
onstrated superior efficacy compared with chemotherapy alone 
as first-line treatment in patients with non-squamous NSCLC, 
reaching the approval for use in this setting (4). However, because 
of substantial redundancy of proangiogenic pathways, patients 
treated with bevacizumab inevitably develop resistance to this 
agent (3).
One strategy for overcoming acquired resistance to bevaci-
zumab is to target simultaneously multiple angiogenic receptors. 
Nintedanib is a new triple angiokinase inhibitor that potently 
blocks the proangiogenic pathways mediated by VEGF receptors, 
platelet-derived growth factor (PDGF) receptors, and fibroblast 
growth factor (FGF) receptors. This review summarizes the 
clinical data emerging from phase I–III clinical studies with nin-
tedanib in NSCLC and in other tumors, focusing on the data that 
led to the recent approval by the European Medicines Agency as 
a second-line treatment in association with docetaxel in patients 
with advanced NSCLC.
PReCLiNiCAL eviDeNCe
Nintedanib (BIBF 1120; methyl (3Z)-3-[[4-[methyl-[2-(4-
methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]- 
2-oxo-1H-indole-6-carboxylate) is a potent, oral angiokinase 
inhibitor that targets the proangiogenic pathways (Figure  1). 
This molecule is an indolinone derivative that blocks adenosine 
triphosphate-binding sites in the kinase domain of proangiogenic 
receptors inhibiting the downstream signaling pathways related 
to neoangiogenesis. Nintedanib is a TKI targeting VEGFR1–3, 
platelet-derived growth factor receptor α (alpha) and β (beta), 
and fibroblast growth factor receptors (FGFR) 1–3 and, in 
addition, it also inhibits the Src family, RET, and FLT3 (5, 6) 
(Figure 2). The three VEGF receptors have different functions, 
but all take part in tumorigenesis, directly stimulating cancer 
stem cell proliferation (6). Moreover, VEGFR-2 is considered the 
crucial receptor involved in initiation of the formation as well as 
the maintenance of tumor vasculature. Preclinical studies with 
nintedanib have shown sustained (>30 h) blockade of VEGFR2 
in vitro and delay or arrest of tumor growth in xenograft models 
of human solid tumors, including lung cancer models (7). The 
specific and simultaneous abrogation of all the pathways targeted 
by nintedanib results in effective growth inhibition of both 
endothelial and perivascular cells, which may be more effective 
than inhibition of endothelial cell growth alone.
Furthermore, signaling by FGF receptors has been identified 
as a possible escape mechanism for tumor angiogenesis when the 
VEGF pathway is disrupted (8). Nintedanib leads to an important 
decrease of microvessel density and pericyte coverage, and this 
leads to a diminished perfusion and thereby to the death of 
tumor cells. In addition, a therapeutic effect may also result from 
inhibition of tumor autocrine and paracrine growth factor loops 
involving VEGF, PDGF, and bFGF.
In a preclinical study with models of lung and pancreatic 
cancer, it has been described that nintedanib does not increase 
the markers of epithelial to mesenchymal transition that usually 
allow tumor cells to switch from one pathway to another. This 
evidence is very important and could explain why this drug does 
not promote the change to a more aggressive tumor subtype and 
does not induce chemotherapy resistance (9).
Following oral administration, nintedanib is rapidly absorbed, 
with a median time to maximum plasma concentration of 1.3 h 
and a terminal half-life of 13.7 h (10). The major route of elimina-
tion of nintedanib is through metabolism, and its metabolites are 
excreted via the biliary system into the feces; urinary excretion is 
minor (1%). Nintedanib metabolism in healthy humans occurs 
predominantly by cleavage of the methyl ester moiety, yielding 
the carboxylate BIBF 1202 (metabolite 1). BIBF 1202 is then 
conjugated to glucuronic acid, yielding 1-O-acylglucuronide 
(metabolite 2). Thus, metabolism of nintedanib is predomi-
nantly cytochrome P450 enzyme independent, which facilitates 
the combination of nintedanib with cytotoxic chemotherapies, 
such as docetaxel, that are metabolized via cytochrome P450 
enzymes (10).
FiGURe 2 | Nintedanib and targeted proangiogenic pathway.
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Phase I, II, and III clinical trials have been conducted in 
NSCLC to investigate the pharmacokinetics, tolerability, and 
efficacy of this triple angiokinase inhibitor (Table 1).
PHASe i STUDieS
Nintedanib showed a manageable safety profile and antitumor 
activity in patients with solid tumors, including NSCLC (13, 16). 
Based on several phase I dose-escalation trials of nintedanib as 
monotherapy, the maximum tolerated dose (MTD) of nintedanib 
was defined as 250 mg twice a day (b.i.d.) in Caucasian patients 
and 200 mg b.i.d. in Japanese patients (17, 18).
In a phase I accelerated titration study, Mross et  al. investi-
gated the MTD and tolerability of nintedanib in 61 patients with 
advanced cancers (16). Nintedanib showed a favorable safety 
profile in this advanced cancer patient population. Twice-daily 
dosing permitted an increase in total dose without additional 
toxicity. Because of its pharmacokinetic profile and absence of 
interaction with CYP450 enzymes, nintedanib was investigated 
in combination with standard cytotoxic chemotherapies, such as 
docetaxel or pemetrexed (11, 19, 20).
Ellis et al. investigated the MTD of continuous oral treatment 
with nintedanib in combination with standard-dose pemetrexed 
(500 mg/m2) (11). Doebele et al. have also investigated the safety, 
tolerability, and MTD of nintedanib (starting dose 50 mg b.i.d.) 
on days 2–21 in combination with carboplatin [area under the 
curve (AUC) 6 mg/ml/min] and paclitaxel (200 mg/m2) on day 
1 of each 21-day cycle, in first-line setting in 26 patients with 
advanced NSCLC (12). The MTD of nintedanib was 200 mg/mq 
b.i.d. in combination with full doses of paclitaxel and carboplatin, 
and dose-limiting toxicities were liver enzyme elevations, throm-
bocytopenia, abdominal pain, and rash. Partial responses were 
observed in 26.9% of patients, and stable disease was observed in 
38.5% of patients.
These trials confirm that splitting the total daily dose into two 
daily administrations increases the total daily exposure without 
additional toxicity. They also showed that 200 mg b.i.d. of nint-
edanib is the recommended dose for continuous daily treatment 
TABLe 1 | Randomized clinical studies with nintedanib in non-small cell lung cancer (NSCLC).
Phase and 
reference
Line of 
treatment
Setting #Patients Treatment Results
Systemic treatment
I; Ellis  
et al. (11)
>1st Advanced 
NSCLC
26 Nintedanib (starting dose 100 bid) days 
2–21 + pemetrexed 500 mg/mq q 21
Maximum tolerated dose (MTD) 200 mg bid
SD 50%
I; Doebele et al. 
(12)
1st Advanced 
NSCLC
26 Nintedanib (starting 50 mg bid) days 
2–21 + carboplatin AUC6 + paclitaxel  
200 mg/mq q 21
MTD 200 mg bid
PR 26.9%; SD 38.5%
II; Reck  
et al. (13)
≥2nd Advanced 
NSCLC, any 
histology
73 Nintedanib 250 mg × bid or nintedanib  
150 mg bid
mPFS (all patients) 6.9 weeks
mOS: 21.9 weeks
Overall survival (OS) 150 vs. 250 mg b.i.d., 20.6 vs. 
29.7 weeks; hazard ratio (HR): 0.693; p = 0.21
III, LUME-Lung 
1; Reck  
et al. (14)
2nd Advanced 
NSCLC, any 
histology
1,314 Docetaxel 75 mg/mq q 21 + nintedanib 
200 mg bid, days 2–21 vs. docetaxel  
75 mg/mq q 21
RR%: 4.7 vs. 3.6
Disease control rate%: 60.2 vs. 44, p < 0.0001
Progression-free survival (PFS): 3.4 vs. 2.7 months, HR: 
0.79, p = 0.0019
OS:10.1 vs. 9.1 months, aHR: 0.94, p = 0.27
III, LUME-Lung 
2; Hanna  
et al. (15)
2nd Advanced 
NSCLC non-
squamous 
histology
713 Docetaxel 75 mg/mq q 21 + nintedanib 
200 mg bid, days 2–21 vs. docetaxel  
75 mg/mq
RR%: 9.1 vs. 8.3
Disease control rate%: 60.9 vs. 53.3, p = 0.039
PFS: 4.4 vs. 3.6 months, HR: 0.83, p = 0.04
OS:12.2 vs. 12.7 months, HR: 1.03, p = 0.79
aOS not statistically different for all histology, but for subgroup non-squamous histology, OS is 12.6 vs. 10.3 months.
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in combination with standard-dose pemetrexed or carboplatin 
and paclitaxel for patients with advanced or metastatic NSCLC 
(11, 12).
In all these phase I studies, nintedanib revealed a similar adverse 
event profile with respect to fatigue and gastrointestinal adverse 
events as compared with other VEGFR TKIs. The predominant 
adverse events were nausea, diarrhea, vomiting, abdominal pain, 
and fatigue of low to moderate intensity during the first 2 months 
of therapy. Dose-limiting toxicities were dose-dependent hepatic 
enzyme elevations that were reversible after discontinuation of 
nintedanib treatment. Only in few patients, liver enzyme eleva-
tions were accompanied by a simultaneous increase in bilirubin. 
In general, common terminology criteria for adverse events 
(version 3.0) grade 3 liver enzyme increases were reported in the 
dose groups of 250 mg twice daily or higher. Severe grade 4 liver 
enzyme elevations were observed only occasionally, and they were 
fully reversible within 2 weeks to treatment discontinuation or 
dose reduction. Fatigue was also reported of a mild-to-moderate 
intensity, instead in the trial of nintedanib with pemetrexed it was 
reported as the most relevant dose-limiting toxicity. There were no 
drug-related bleeding events. Hypertension or thromboembolic 
events were rare and did not suggest an increased frequency as a 
consequence of therapy with nintedanib. There was no increase 
in hematologic toxicity observed when nintedanib was combined 
with chemotherapy. Unlike some other oral angiogenesis inhibi-
tors, nintedanib did not seem to cause relevant skin abnormalities 
and no hand-foot syndrome was observed.
PHASe ii STUDieS
Reck et al. conducted a phase II double-blinded, two-arm, ran-
domized monotherapy trial with nintedanib (13). Patients with 
locally advanced or metastatic relapsed NSCLC of any histology 
after failure of first- or second-line chemotherapy with an Eastern 
Cooperative Oncology Group (ECOG) performance status 
(PS) 0–2 were randomized to continuous 150 or 250  mg b.i.d. 
nintedanib treatment until disease progression. Progression-free 
survival (PFS) and overall response rate were primary end points. 
Secondary end points included pharmacokinetic profiles of nint-
edanib, safety, and overall survival (OS). There was no significant 
difference in the PFS and the OS between the two groups. The 
results of this trial demonstrate that nintedanib in patients with 
ECOG 0–1 reaches effectiveness comparable to historical phase 
II data of other VEGFR inhibitors in a similar patient population: 
median PFS was 2.9 months with nintedanib, 2.8 months with 
sunitinib (21), 2.8 months with sorafenib (22), 2.6 months with 
vandetanib (23), and 3.5 months with vatalanib (24). The toxicity 
profile in this study was similar to that seen in phase I trials (17, 
18). The majority of the adverse events were mild-to-moderate 
gastrointestinal symptoms with reversible hepatic toxicity. 
Tolerability was comparable between the two doses, with the 
exception of a higher frequency of liver enzyme elevations in the 
higher dose group.
PHASe iii STUDieS
Two randomized prospective clinical trials have been conducted 
to evaluate the efficacy of nintedanib in patients with advanced 
NSCLC. The LUME-Lung 1 was a large multicenter double-
blind, placebo-controlled, phase III trial randomizing patients 
with NSCLC to second-line docetaxel plus placebo (n =  659) 
or docetaxel plus nintedanib (n  =  655) (14). The primary 
end point was PFS by central independent review, and the 
secondary end point was OS; additional secondary end points 
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included investigator-assessed PFS, tumor response by central 
review and investigator assessment, safety, and patient-reported 
quality of life (QoL). Patients were randomized in a 1:1 ratio to 
investigational arm of nintedanib 200  mg b.i.d. plus standard 
docetaxel therapy 75 mg/m2 vs. placebo plus standard docetaxel 
therapy. A total of 1,314 patients were randomized: 655 assigned 
to experimental arm and 659 to standard arm. Patients were 
stratified by histology, ECOG PS, prior bevacizumab treatment, 
and the presence of brain metastases allowed if stable. Exclusion 
criteria were as follows: previous treatment with docetaxel or 
other VEGF inhibitors therapy (with the exception of bevaci-
zumab), active and unstable brain metastasis or radiographic 
evidence of cavitary or necrotic tumors. Baseline demographics 
were well balanced between both arms. In this trial, the addi-
tion of nintedanib to docetaxel significantly improved PFS 
in the total study population (median 3.4  months [95% CI: 
2.9–3.9] vs. 2.7 months [2.6–2.8]; hazard ratio (HR): 0.79 [95% 
CI: 0.68–0.92], p = 0.0019). The benefit in PFS was consistent, 
regardless of gender, age, ethnicity, or PS.
Moreover, the addition of nintedanib improved median OS in 
patients with adenocarcinoma (12.6 months [95% CI: 10.6–15.1] 
vs. 10.3 months [95% CI: 8.6–12.2]; HR: 0.83 [95% CI: 0.70–0.99], 
p =  0.0359). The prolongation of OS was consistent with the 
improvement of 1-year survival rate from 45 up to 53% and 2-year 
survival rate from 19 up to 26%. OS was also increased in patients 
with adenocarcinoma histology who progressed within 9 months 
after start of first-line treatment (median OS increased from 7.9 
to 10.9  months corresponding to a HR of 0.75 and p value of 
0.0073) and in patients refractory to first-line chemotherapy. 
In this group of poor prognosis patients, an advantage of more 
than 3 months was observed with the addition of nintedanib to 
docetaxel compared to docetaxel alone (9.8 vs. 6.3 months, HR 
of 0.62, p = 0.0246). There was no difference in OS in the total 
study population (median 10.1  months [95% CI: 8.8–11.2] vs. 
9.1 months [8.4–10.4]; HR: 0.94 [95% CI: 0.83–1.05], p = 0.2720) 
and in patients with squamous cell carcinoma between both arms. 
Finally, the investigation of the interaction between treatment and 
tumor burden showed that a greater tumor burden was associated 
with a greater treatment effect for docetaxel and nintedanib. In 
addition, a significant improvement in disease control rate (60.2 
vs. 44%) in favor of nintedanib plus docetaxel was observed in 
adenocarcinoma patients. Adverse events more common in the 
docetaxel plus nintedanib group than the docetaxel plus placebo 
group were as follows: diarrhea (all grades: 42.3 vs. 21.8%; 
grade ≥ 3 6.6 vs. 2.6%), increases in alanine aminotransferase (all 
grades, 28.5 vs. 8.4%; grade ≥ 3 7.8 vs. 0.9%), nausea (all grades, 
24.2 vs. 18.0%; grade ≥  3, 0.8 vs. 0.9%), increases in aspartate 
aminotransferase (all grades, 22.5 vs. 6.6%; grade ≥  3, 3.4 vs. 
0.5%), decreased appetite (all grades, 22.2 vs. 15.6%; grade ≥ 3, 
1.4 vs. 1.2%), and vomiting (all grades 16.9 vs. 9.3%; grade ≥ 3 
0.8 vs. 0.5%). There was no statistically significant increase in the 
incidence of bleeding and hypertension events by the addition of 
nintedanib (25). Moreover, the significant OS benefit observed 
with the addition of nintedanib to docetaxel therapy was achieved 
with no detrimental effect on patient self-reported QoL, with 
significant reductions in some pain items with nintedanib vs. 
placebo (26).
LUME-Lung 2 was a multicenter, randomized, double-
blinded phase III study that investigated the efficacy and safety 
of nintedanib in combination with pemetrexed vs. placebo plus 
pemetrexed in patients with locally advanced or metastatic non-
squamous NSCLC with relapse or failure after chemotherapy 
(15). A total of 713 patients were randomized 1:1 to experimental 
arm (353 patients) and to standard arm (360 patients). The pri-
mary end point was centrally reviewed PFS, the secondary end 
points were OS, investigator-assessed PFS, objective response rate 
(ORR), safety, and QoL. The study enrolled patients with ECOG 
PS 0–1 without active brain metastases, cavitary or necrotic 
tumors, and clinically significant hemoptysis, not previously 
treated with VEGF inhibitors (except bevacizumab). Baseline 
patient characteristics were balanced between both arms for age, 
gender, PS, histology type, and prior bevacizumab treatment. 
All randomized patients were included in the intention-to-treat 
(ITT) population. The study was designed to have 90% power to 
demonstrate a significant (27.5%) improvement in PFS with a HR 
of 0.78 after 713 PFS events.
The analysis suggested that the primary end point of centrally 
assessed PFS would likely not be met; however, there were no 
safety concerns. Ongoing patients were unblinded and follow-up 
was continued per protocol. Analysis of the primary end point 
PFS by independent central review was conducted after 498 
events had occurred, and analysis of the secondary end point 
OS was conducted after 436 events had occurred. The primary 
end point of this phase III trial was met even though the study 
was stopped prematurely. ITT analysis of the primary end point 
showed that treatment with nintedanib plus pemetrexed resulted 
in a significant prolongation of PFS compared with placebo plus 
pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value 
of 0.04). Disease control rate was also increased significantly in 
nintedanib-treated group (61 vs. 53%, with an odds ratio of 1.37 
and a p value of 0.039). No difference in OS was seen between 
the arms. There was no increase in serious side effects in the 
combination arm. However, there was an increase in the inci-
dence of diarrhea and elevated liver enzymes, each of which were 
reversible. There was no difference between the arms in terms of 
the incidence of hypertension, bleeding, thrombosis, mucositis, 
or neuropathy.
NiNTeDANiB iN OTHeR TUMORS
Due to the important rule of angiogenesis pathways identified in 
cancer development, Nintedanib has also been evaluated in other 
tumors (Table 2).
Small Cell Lung Cancer
A phase II study evaluated nintedanib activity in 24 patients 
with small cell lung cancer (SCLC) relapsed after one or two 
lines of chemotherapy or chemoradiotherapy (27). Eight patients 
received only one prior chemotherapy. Nintedanib was adminis-
tered at 200 mg twice daily until disease progression or toxicity. 
ORR, the primary end point, was 5% [95% CI: 0.1–22.8]. Median 
PFS was 1  month and OS was 9.8  months. The most frequent 
drug-related adverse events included hepatic enzyme elevation 
(86%), anemia (73%), anorexia (59%), and nausea (50%). Most 
TABLe 2 | Studies with nintedanib in other tumors.
Phase and 
reference
Line of 
treatment
Setting #Patients Treatment Results
Systemic treatment
II; Han  
et al. (27)
≥2nd Relapsed small 
cell lung cancer
24 Nintedanib 200 mg × 2/day Objective response rate = 5%
Hepatic enzyme elevation 86%
II; Palmer  
et al. (28)
1st Unresectable 
HCC
93 Nintedanib 200 mg × 2/day vs. sorafenib Time to progression: 5.5 vs. 3.8 months
Overall survival (OS): 11.9 vs. 11.4 months
Comparable toxicities
II; Eisen  
et al. (29)
1st Advanced RCC 96 Nintedanib 200 mg × 2/day vs. sunitinib Progression-free survival (PFS) at 9 months 43.1 
vs. 45.2%
OS: 20.4 vs. 21.2 months
Comparable toxicities
II; Norden  
et al. (30)
≥2nd Recurrent 
glioblastoma
36 Nintedanib 200 mg × 2/day No responses
PFS at 3 (prior bevacizumab) and 6 (no prior 
bevacizumab) months = 0%
II; Droz  
et al. (31)
≥2nd Prostate cancer 81 Nintedanib 150 or 250 mg × 2/day PSA decrease under 50% = 5.6%
PFS: 73.5–76 days
II; Van Cutsem 
et al. (32)
1st Colorectal 
cancer
126 mFOLFOX6 + nintedanib 200 mg × 2/day or 
bevacizumab 5 mg/kg every 14 days
PFS at 9 months: 62.1 vs. 70.2%
II; Ledermann 
et al. (33)
≥2nd Ovarian cancer 83 Nintedanib 250 mg × 2/day vs. placebo for up to 
9 months as maintenance following chemotherapy
% of patients progression free at 36 weeks: 16.3 
vs. 5%
Grade 3 or 4 hepatotoxicity 51.2 vs. 7.5%
III, AGO-OVAR 
12; du Bois 
et al. (34)
1st Ovarian cancer 1,366 Carboplatin (AUC 5/6) + paclitaxel (175 mg/mq) 
d1 + nintedanib 200 mg × 2/day or placebo days 
2–21 q21 × 6 cycles → nintedanib or placebo 
maintenance for up to 2 years
PFS: 17.2 vs. 16.6 months, hazard ratio: 0.84, 
p = 0.024
G3 diarrhea 21 vs. 2%, G4 neutropenia 22 vs. 
16%, G4 thrombocytopenia 6 vs. 2%
PSA, prostate-specific antigen.
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toxicities were mild and manageable. Grade 3 hepatic enzyme 
elevation occurred in five patients (23%). The authors concluded 
that nintedanib exhibited only a modest activity in relapsed or 
refractory SCLC.
Hepatocellular Carcinoma
A phase II study was designed to compare safety and activity of 
nintedanib 200 mg b.i.d. vs. sorafenib 400 mg b.i.d. in 93 patients 
with unresectable hepatocellular carcinoma and Child-Pugh 
A  score, randomized in a 2:1 ratio (28). Time to progression, 
the primary objective, was comparable between nintedanib and 
sorafenib (median 5.5 vs. 3.8 months; HR: 1.05 [95% CI: 0.63–
1.76]). Median OS was 11.9 vs. 11.4 months, respectively (HR: 
0.88 [95% CI: 0.52–1.47]). More patients treated with sorafenib 
had grade ≥ 3 adverse events (68 vs. 90%). Toxicities leading to 
dose reduction were higher with sorafenib (19 vs. 42%), whereas 
side effects leading to drug discontinuation were higher with 
nintedanib (45 vs. 23%). Rash was reported in >15% of patients 
only in the sorafenib arm.
Renal Cell Carcinoma
A phase II study evaluated activity and tolerability of first-line 
nintedanib 200  mg twice daily vs. standard sunitinib in 96 
patients with advanced renal cell carcinoma, randomized in a 2:1 
ratio (29). The trial would also test possible electrocardiographic 
changes, particularly in QTc, during nintedanib assumption. 
PFS at 9  months, the primary objective, was 43.1 vs. 45.2% 
(p = 0.85) for nintedanib vs. sunitinib. Median OS was 20.4 vs. 
21.2 months (HR: 0.92; 95% CI: 0.54–1.56; p = 0.76). Toxicities 
were comparable between the two treatments. Nintedanib was 
associated with lower incidences of some adverse events typical 
of antiangiogenic TKIs, such as hypertension, hypothyroidism, 
hand-foot syndrome, cardiac disorders, and hematological 
abnormalities.
Glioblastoma
Activity of nintedanib was also explored in patients with recurrent 
glioblastomas, but the results were disappointing. In a phase II 
study, 36 patients, stratified based on prior bevacizumab, received 
nintedanib 200  mg twice daily (30). There were no responses, 
and PFS at 3 (prior bevacizumab) and 6 (no prior bevacizumab) 
months was 0%.
Castration-Resistant Prostate Cancer
Modest activity was noted with nintedanib 150 or 250  mg 
twice daily in 81 castration-resistant prostate cancer patients 
pretreated with docetaxel chemotherapy (31). Only 5.6% of 
patients treated with nintedanib 250  mg obtained a prostate-
specific antigen (PSA) decrease of at least 50%. Median PFS 
was 73.5 and 76 days with nindetanib 150 and 250 mg, respec-
tively. Toxicities included gastrointestinal disorders, asthenia, 
TABLe 3 | Ongoing studies with nintedanib.
Phase Line of 
treatment
Setting #Patients Treatment endpoints
Systemic treatment
I Neoadjuvant Resectable non-small cell lung 
cancer stage IB–IIIA
45 Cisplatin + docetaxel + nintedanib Major pathologic response rate
Toxicity of nintedanib given with 
cisplatin and docetaxel
II/III 1st Unresectable pleural 
mesothelioma
537 Cisplatin-pemetrexed + nintedanib or 
placebo → nintedanib or placebo maintenance
Progression-free survival (PFS)
III Advanced Advanced colorectal cancer 764 Monotherapy with nintedanib 200 mg × 2/day vs. 
placebo (prior regorafenib allowed)
PFS and overall survival
III Advanced Advanced colorectal cancer 100 Nintedanib alone or in combination with 
capecitabine
PFS
II 1st or 2nd Advanced HER2-negative 
breast cancer
252 Docetaxel d1 ± nintedanib 200 mg × 2/day, days 
2–21
PFS
I Advanced Refractory solid tumors 18 Nintedanib + pembrolizumab Maximum tolerated dose of nintedanib
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hypertension, and reversible elevated transaminases. A phase I 
trial tested nintedanib in association with docetaxel (75 mg/m2 
every 3 weeks) and prednisone in castration-resistant prostate 
cancer patients (19), suggesting the dose of 200 mg twice daily 
for future investigations. Among 19 assessable patients, 13 
(68.4%) showed a ≥50% reduction in PSA levels from baseline. 
Pharmacokinetic analysis showed no interactions between 
nintedanib and docetaxel/prednisone.
Metastatic Colorectal Cancer
A phase I/II study tested nintedanib +  mFOLFOX6 or beva-
cizumab +  mFOLFOX6 in the first-line treatment of patients 
with advanced colorectal cancer (32). In the phase II of the 
study, nintedanib was given at 200 mg twice daily. Overall, 126 
patients were randomized in a 2:1 ratio into the nintedanib vs. 
bevacizumab arm. PFS at 9 months, the primary objective, was 
62.1 vs. 70.2%, while objective response was 63.5 vs. 56.1%. The 
incidence of serious adverse events was 37.6% with nintedanib 
and 53.7% with bevacizumab. The pharmacokinetics of nint-
edanib and the components of mFOLFOX6 were unaffected by 
their combination.
Ovarian Cancer
A randomized phase II study was conducted with nintedanib 
in 83 relapsed ovarian cancer patients. In this study, women 
treated with nintedanib as maintenance therapy at 250 mg twice 
daily for up to 9  months after chemotherapy were less likely 
to experience disease progression compared to those treated 
with placebo (33). At 36 weeks, 16.3% of women taking nint-
edanib were progression free, compared to 5% of those taking 
placebo (HR: 0.65; 95% CI: 0.42–1.02; p = 0.06). Two patients 
continued nintedanib for another year or more. More patients 
on nintedanib experienced diarrhea, nausea, or vomiting (no 
grade 4). There was a higher rate of grade 3 or 4 hepatotoxicity 
in patients on nintedanib (51.2%) compared with patients on 
placebo (7.5%; p < 0.001).
LUME-Ovar 1, also named AGO-OVAR 12, is a phase III 
study testing association of first-line chemotherapy plus nint-
edanib or placebo in patients with advanced ovarian carcinoma 
(34). The trial recruited 1,366 patients with FIGO IIB-IV ovarian 
carcinoma and primary debulking surgery to receive in a 2:1 ratio 
of six cycles of carboplatin (AUC 5 or 6 mg/dl/min) and paclitaxel 
(175 mg/m2) on day 1 every 3 weeks plus nintedanib 200 mg twice 
daily on days 2–21 of each cycle or placebo. The biological agent 
or placebo were given for up to 120 weeks. Primary end point 
was PFS by investigator assessment in the ITT population. As a 
result, 53% of 911 patients in the nintedanib group experienced 
disease progression or death compared with 58% of 455 patients 
in the placebo group. Median PFS was significantly longer with 
nintedanib than placebo (17.2  months [95% CI: 16.6–19.9] vs. 
16.6 months [13.9–19.1]; HR: 0.84 [95% CI: 0.72–0.98]; p = 0.024). 
The most common adverse events were gastrointestinal, such as 
grade 3 diarrhea in 21% of patients receiving nintedanib vs. 2% 
in the placebo group, and hematological (neutropenia of grade 3 
in 20% and grade 4 in 22% of patients receiving nintedanib vs. 20 
and 16% in the placebo group, respectively; thrombocytopenia 
12 and 6% vs. 5 and 2%; anemia 12 and 1% vs. 6 and 1%). Serious 
adverse events were reported in 42% with nintedanib and 34% 
with placebo; 3% of patients receiving nintedanib experienced 
serious adverse events associated with death compared with 4% 
in the placebo group.
ONGOiNG CLiNiCAL STUDieS  
wiTH NiNTeDANiB
Nintedanib is currently under investigation in various types 
of tumor (Table  3). In neoadjuvant setting, a phase I study is 
evaluating the safety of nintedanib in combination with cisplatin 
and docetaxel before surgery in patients with stages I–III NSCLC 
[http://ClinicalTrials.gov: NCT02225405]. LUME-Meso is a 
rando mized double-blind phase II/III study testing safety and 
efficacy of nintedanib in 537 naïve patients with unresectable 
pleural mesothelioma (35). Treatment consists of six courses of 
chemotherapy with cisplatin 75 mg/m2 and pemetrexed 500 mg/
m2 on day 1 plus nintedanib 200 mg b.i.d. on days 2–21 of each cycle 
or placebo. Following maintenance with biologic agent, placebo 
is given to patients with controlled disease. Primary end point is 
PSF, and secondary end points include OS, objective response, 
8Manzo et al. Development of Nintedanib, Available Evidences
Frontiers in Medicine | www.frontiersin.org December 2016 | Volume 3 | Article 68
and disease control rate. Preliminary results are expected in 2019. 
LUME-Colon 1 is a double-blind randomized phase III study 
evaluating monotherapy with nintedanib and best supportive care 
(BSC) vs. placebo and BSC in patients with refractory advanced 
colorectal cancer pretreated with standard chemotherapies 
and biologic agents (36). ECOG PS 0–1 and life expectancy of 
minimum 12  weeks are required. Estimated accrual is of 764 
patients. Prior regorafenib is allowed. Patients are stratified based 
on previous regorafenib, time from onset of metastatic disease 
to randomization (less or more than 24  months), and region. 
Nintedanib is administered at 200 mg twice daily vs. placebo in a 
1:1 randomization. Primary outcomes are PFS by central review 
assessment and OS, with objective tumor response and disease 
control as secondary end points. Other assessments include 
frequency and severity of adverse events, changes in laboratory 
parameters, health-related QoL, and biomarker analyses to better 
define predictiveness of response and drug resistance mechanisms. 
Final results are soon expected. LUME-Colon 2 is a phase II study 
assessing nintedanib alone or in combination with capecitabine in 
patients with refractory metastatic colorectal cancer after failure 
of at least two lines of standard treatment. Primary end point is 
PFS. Estimated enrollment is 100 patients. Results are expected in 
2017 [http://ClinicalTrials.gov: NCT02780700]. A phase II study 
is testing first- or second-line docetaxel ± nintedanib in patients 
with HER2-negative metastatic or locally recurrent breast cancer. 
Docetaxel 75 mg/m2 every 3 weeks could be increased to 100 mg/
m2 in the arm without nintedanib. Nintedanib is administered 
at 200 mg twice daily from day 2 of each cycle. Primary objec-
tive is PFS. Secondary end points are response rate, OS, QoL, 
and pharmacokinetic analyses. Estimated enrollment is 252 
patients, and results are soon expected [http://ClinicalTrials.gov: 
NCT01658462].
Finally, an ongoing phase I trial is testing nintedanib and 
pembrolizumab in refractory solid tumors patients to define the 
toxicity profile of such combination [http://ClinicalTrials.gov: 
NCT02856425].
DiSCUSSiON AND CONCLUSiON
Two randomized phase III clinical trials have evaluated to date 
the efficacy of nintedanib in patients with advanced NSCLC. The 
LUME-Lung 1 trial have showed, for the first time, an OS benefit 
in patients with advanced NSCLC from the addition of a targeted 
agent to chemotherapy in the second-line setting. In this trial, 
the addition of nintedanib to docetaxel significantly improved 
median OS in patients with adenocarcinoma histology (from 10.3 
to 12.6 months), with a greater advantage in patients who pro-
gressed within 9 months after start of first-line treatment (from 
7.9 to 10.9  months) and in patients who were most refractory 
to first-line chemotherapy (from 6.3 to 9.8 months). Moreover, 
nintedanib plus docetaxel improved PFS and disease control in 
the total study population. These results were partially confirmed 
by the LUME-Lung 2 trial that, despite early closure, showed that 
nintedanib plus pemetrexed resulted in a significant prolonga-
tion of PFS and disease control rate, while no difference in OS 
was seen between the arms, probably due to the final low power 
of the study. On these bases, the combination of docetaxel and 
nintedanib can be considered a new option for the second-line 
treatment for patients with advanced NSCLC with adenocarci-
noma histology (37).
However, there are several issues that need to be addressed, 
including the following: (a) how to improve the tolerability profile 
of the combination of docetaxel and nintedanib; (b) the role of 
nintedanib in other settings, such as first line and neoadjuvant; (c) 
the feasibility of combining nintedanib with other drugs; (d) the 
activity of nintedanib in other tumors; and (e) the identification 
of predictive factors.
The most frequent adverse events of nintedanib as single agent 
were nausea, diarrhea, vomiting, increases in liver enzymes, and 
fatigue, generally of low to moderate intensity, while hypertension 
or thromboembolic events were rare. Combination of nintedanib 
with docetaxel revealed a similar toxicity profile as compared to 
nintedanib monotherapy, except for docetaxel-related toxicities. 
Chemotherapy with docetaxel 75  mg/mq administered once 
every 3 weeks has been proven to be a reasonable therapeutic 
choice for the second-line treatment of patients with advanced 
NSCLC, but myelosuppression is extremely frequent and severe: 
weekly scheduling of docetaxel has demonstrated to improve the 
toxicity profile of the drug in pretreated NSCLC patients without 
decreasing antitumor activity (38). Therefore, the addition of 
nintedanib to weekly docetaxel could be an attractive schedule 
to maintain the therapeutic efficacy of the combination with a 
better toxicity profile. An Italian multicenter, prospective, open-
label study with two “cohorts” is evaluating the efficacy and safety 
profile of nintedanib plus docetaxel in patients with non-squa-
mous NSCLC in stage IIIB/IV with two different combination 
schedules, including a weekly schedule of docetaxel (SENECA 
trial): the results of this trial should answer the question of the 
feasibility and activity of the combination of nintedanib with 
weekly docetaxel.
In other settings, a phase I study investigated nintedanib com-
bined with paclitaxel (200 mg/mq) and carboplatin (AUC 6 mg/
ml/min), in first-line setting in 26 patients with advanced NSCLC 
(21). This combination was well tolerated, without drug-to-drug 
interactions and demonstrated promising preliminary efficacy in 
patients with advanced NSCLC, supporting further investigation 
in patients with NSCLC. In neoadjuvant setting, a phase I study is 
evaluating the safety of nintedanib in combination with cisplatin 
and docetaxel before surgery in patients with stage I–III NSCLC.
A number of studies are evaluating the feasibility of the 
combination of nintedanib and other classes of drugs, including 
angiogenesis inhibitors such as bevacizumab, EGFR inhibitors 
such as afatinib, and immune checkpoint inhibitors such as 
pembrolizumab. The good safety profile of the drug allows to use 
nintedanib also in special populations, such as elderly patients, in 
combination with other chemotherapeutic agents: the VENUS-1 
and VENUS-2 are dose-escalation trials to evaluate the feasibility 
of the combination of nintedanib with vinorelbine or with carbo-
platin and vinorelbine in elderly patients with advanced NSCLC.
Ongoing studies will clarify the activity of nintedanib in other 
tumors, including mesothelioma, colon, breast, ovarian, cervix, 
pancreatic cancer, and HCC.
Identifying molecular biomarkers that can predict a response 
to nintedanib remains an important goal to maximize the clinical 
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benefit of this agent. A phase II study is ongoing to examine the 
value of FGFR1 gene amplification as a predictor of nintedanib effi-
cacy in patients with squamous cell NSCLC [http://ClinicalTrials.
gov: NCT01948141]. Additional studies are planned that include 
translational approaches to identify more detailed mechanisms of 
action for nintedanib.
In conclusion, nintedanib is an effective second-line treatment 
in combination with docetaxel for patients with lung adenocar-
cinoma, also refractory to first-line chemotherapy. Future chal-
lenges are to indentify predictive factors to help the decision of 
using antiangiogenic agents in patients.
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